domingo, 8 de enero de 2017

Telomeres and telomerase in the clinical management of colorectal cancer. - PubMed - NCBI

Telomeres and telomerase in the clinical management of colorectal cancer. - PubMed - NCBI
 2016 Oct 19. [Epub ahead of print]

Telomeres and telomerase in the clinical management of colorectal cancer.

Abstract

Colorectal cancer (CRC) is the third most common cancer worldwide. Our aim is to describe the state of the art about the role of telomeres and telomerase in the clinical management of CRC and its potential utility as prognostic and diagnostic biomarkers and targets of new treatments. Telomere length could be a new diagnostic marker as an anomalous behavior is observed in peripheral blood cells when CRC patients and healthy people are compared. Moreover, telomeres and telomerase may be used as diagnostic markers considering that universal changes appear along the CRC process. Currently, new therapeutic cancer approaches are focused on inhibiting the maintenance of telomere length, choosing as targets telomerase -or its subunits- or the Shelterin complex. The goal of these therapies is the shortening of telomeres and the induction of cell senescence. Telomeres and telomerase emerge as useful molecular tools in the clinical management of CRC.

KEYWORDS:

Colorectal cancer; Colorectal cancer therapy; Diagnostic marker; Prognostic marker; Telomerase activity; Telomere length
PMID:
 
27761787
 
DOI:
 
10.1007/s12094-016-1559-0
[PubMed - as supplied by publisher]

No hay comentarios:

Publicar un comentario